Preliminary acquisition proposal disclosed by LakeShore Biopharma (YSBPW) in 6-K

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd submitted a Form 6-K reporting that it has issued a press release about receiving a preliminary, non-binding proposal to acquire the company. The filing itself does not include the proposal terms, but it confirms that an acquisition approach has been made and that details are described in an attached press release.

Insights

M&A and corporate actions analyst

LakeShore Biopharma discloses a preliminary, non-binding acquisition approach.

LakeShore Biopharma has filed a Form 6-K noting a press release titled "LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company." This indicates that a party has expressed interest in acquiring the company, but only at an early and non-binding stage. No pricing, structure, or counterparty details are provided in this excerpt.

Because the proposal is described as both preliminary and non-binding, there is no assurance that a definitive agreement or transaction will result. The filing mainly serves to inform investors that an approach has been received and publicly acknowledged through a press release. Subsequent disclosures in future filings or press releases would be needed to outline any agreed terms, if negotiations progress.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/18/2025 - 08:36 AM Learn about SEC filing dates

FAQ

What did LakeShore Biopharma Co., Ltd (YSBPW) report in this Form 6-K?

LakeShore Biopharma reported that it issued a press release titled "LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company", indicating it has received an initial acquisition proposal.

What type of proposal did LakeShore Biopharma (YSBPW) receive?

The company received a preliminary non-binding proposal to acquire the company, as described in the attached press release listed as Exhibit 99.1.

Where can investors find more details on the LakeShore Biopharma acquisition proposal?

More details are contained in Exhibit 99.1, described as the press release "LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company."

Who signed the LakeShore Biopharma (YSBPW) Form 6-K related to the acquisition proposal?

The Form 6-K was signed on behalf of LakeShore Biopharma Co., Ltd by Rachel Yu, who is identified as Director and Chief Financial Officer.

When was this LakeShore Biopharma Form 6-K regarding the proposal dated?

The Form 6-K is dated August 18, 2025, reflecting the timing of the company’s report about the preliminary non-binding acquisition proposal.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒          Form 40-F  ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: August 18, 2025

2